Mark J. Ratain to Lymphoma
This is a "connection" page, showing publications Mark J. Ratain has written about Lymphoma.
Connection Strength
0.475
-
Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
Score: 0.172
-
Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
Score: 0.097
-
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86.
Score: 0.062
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.054
-
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32.
Score: 0.037
-
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
Score: 0.034
-
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report. Gynecol Oncol. 1989 Dec; 35(3):391-4.
Score: 0.019